| Outcome Measures: |
Primary: Proportion of subjects with HbA1c<7% at 12w, From enrollment to the end of treatment at 12 weeks | Secondary: The proportion of subjects with HbA1c<7% at week 24, From enrollment to the end of treatment at 24 weeks|The proportion of subjects with HbA1c<6.5% at 12 week, From enrollment to the end of treatment at 12 weeks|The proportion of subjects with HbA1c<6.5% at 24 week, From enrollment to the end of treatment at 24 weeks|Changes in HbA1c compared to baseline at 12 weeks, From enrollment to the end of treatment at 12 weeks|Changes in HbA1c compared to baseline at 24 weeks, From enrollment to the end of treatment at 24 weeks|Changes in fingertip blood glucose (seven point blood glucose spectrum) compared to baseline at 4w, 8w, 12w, and 24w, From enrollment to the end of treatment at 4/8/12/24 weeks|Changes in 2hPPG compared to baseline at 4w, 8w, 12w, and 24w, From enrollment to the end of treatment at 4/8/12/24 weeks|Changes in FBG compared to baseline at 4w, 8w, 12w, and 24w, From enrollment to the end of treatment at 4/8/12/24 weeks|Changes in systolic pressure compared to baseline at 4w, 8w, 12w, and 24w, From enrollment to the end of treatment at 4/8/12/24 weeks|Changes in diastolic pressure compared to baseline at 4w, 8w, 12w, and 24w, From enrollment to the end of treatment at 4/8/12/24 weeks|Changes in body weight compared to baseline at 4w, 8w, 12w, and 24w, From enrollment to the end of treatment at 4/8/12/24 weeks|Changes in waist circumference compared to baseline at 4w, 8w, 12w, and 24w, From enrollment to the end of treatment at 4/8/12/24 weeks|Changes in eGFR compared to baseline at 4w, 8w, 12w, and 24w, From enrollment to the end of treatment at 4/8/12/24 weeks|Changes in C-peptide levels during the 12 and 24 weeks compared to baseline during abdominal and 2-hour postprandial periods, From enrollment to the end of treatment at 12 and 24 weeks|Changes in insulin levels during the 12 and 24 weeks compared to baseline during abdominal and 2-hour postprandial periods, From enrollment to the end of treatment at 12 and 24 weeks
|
